Champions Oncology Research and Development Expenses 2010-2024 | CSBR

Champions Oncology research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Champions Oncology Research and Development Expenses 2010-2024 | CSBR

Champions Oncology research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$89B
Takeda Pharmaceutical (TAK)$47.2B
Merck (MKGAF)$23.7B
Astellas Pharma (ALPMY)$22.1B
Summit Therapeutics (SMMT)$17.8B
Sandoz Group AG (SDZNY)$17.6B
United Therapeutics (UTHR)$15.2B
Shionogi (SGIOY)$13.1B
Neurocrine Biosciences (NBIX)$12.1B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$6.2B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.1B
Corcept Therapeutics (CORT)$4.4B
Crinetics Pharmaceuticals (CRNX)$4.2B
Dyne Therapeutics (DYN)$3.4B
PTC Therapeutics (PTCT)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Harrow (HROW)$1.6B
Cassava Sciences (SAVA)$1.5B